...All right. Thank you for joining on the first day of the Oppenheimer Healthcare Conference. My name is Frank Brisebois. I'm one of the analysts here -- biotech analysts here at Oppenheimer. This year the next presenter is Bobby Azamian; he's the CEO of Tarsus Pharmaceuticals. It's the company we cover with an outperformed rating; very interesting play in ophthalmology. Long story short, reminds me a little bit of a dry eye with no competition, which is then an objective endpoint in the trial, which is pretty shocking here. So I'll let Bobby take it away here. If you would like to ask any questions, you can put it in the -- I think there's an icon on your chat and I will do my best to get to them. But in terms of format, yes, we're going to do -- Bobby is going to have a presentation for about five minutes or so and then we'll just jump right into Q&A. So thank you very much for joining, Bobby. I know it's been a busy time, I'm sure, for everyone involved in this space. So thanks for taking...
